Member Info for Cliveas

Seems to me STI are the big boy in this!

Goldstone Change of Holdings Stratex International Plc, the AIM-quoted exploration and development company focused on gold and base metals in East Africa, West Africa and Turkey, where it holds a significant interest in a producing gold mine, advises that Goldstone Resources Limited ("Goldstone"; AIM: GRL), in which the Company holds a 33.45% interest, has today announced that Red Rock Resources plc ("Red Rock Resources") and Metal Tiger plc ("Metal Tiger") will jointly acquire Unity Mining Ltd's 19.29% shareholding (12,013,173 ordinary shares) in Goldstone (the "Transaction") for an aggregate consideration of £225,000. The Transaction is expected to complete on 3rd May 2016, and a result, Red Rock Resources and Metal Tiger will hold 9.65% and 13.26% of the issued share capital of Goldstone respectively. The Transaction will have no impact on Stratex's 33.45% interest in the voting rights of Goldstone.

Wrong: Goldstone Change of Holdings Stratex International Plc, the AIM-quoted exploration and development company focused on gold and base metals in East Africa, West Africa and Turkey, where it holds a significant interest in a producing gold mine, advises that Goldstone Resources Limited ("Goldstone"; AIM: GRL), in which the Company holds a 33.45% interest, has today announced that Red Rock Resources plc ("Red Rock Resources") and Metal Tiger plc ("Metal Tiger") will jointly acquire Unity Mining Ltd's 19.29% shareholding (12,013,173 ordinary shares) in Goldstone (the "Transaction") for an aggregate consideration of £225,000. The Transaction is expected to complete on 3rd May 2016, and a result, Red Rock Resources and Metal Tiger will hold 9.65% and 13.26% of the issued share capital of Goldstone respectively. The Transaction will have no impact on Stratex's 33.45% interest in the voting rights of Goldstone.

MTR c 13% RRR c 10% STI c 33%? We have cash to match MTR and income too! Carve up the weak?

Way to expose yourself to the MTR revolution! Merger of several companies on the cards here all involving gold! IMHO

We own 33%: STRATEGIC ACQUISITION - GOLDSTONE RESOURCES Metal Tiger plc (LON:MTR) the London Stock Exchange AIM listed investor in strategic natural resource projects is pleased to announce the Company's participation in the acquisition of 12,013,173 shares of Goldstone Resources Ltd ("Goldstone Resources")(AIM:GRL) by the Company and Red Rock Resources plc ("Red Rock")(AIM:RRR) at a price of 1.87p per Goldstone Resources share. The acquired shares total 19.29% of the issued share capital of Goldstone Resources, and upon completion of the acquisition Red Rock will acquire and own 6,006,587 GRL shares (9.645% of GRL) and MTR will acquire 6,006,586 shares (9.645% of GRL). Metal Tiger already owns 2,250,000 shares in Goldstone Resources, therefore following the additional acquisition Metal Tiger will own 8,256,586 shares representing 13.26% of Goldstone Resources. Goldstone Resources is an exploration company with exploration skills that focus on West and Central Africa. The assets include the Homase/Akrokerri project adjoining and to the East and North of AngloGold Ashanti's Obuasi mine in the Ashanti Gold Belt in Ghana. The project has a JORC Mineral Resource of 602,000 oz of gold at 1.77 g/t. Other licenses are held in Gabon and Senegal. The consideration for the acquisition is £225,000. Of this consideration £112,500 is payable in cash by Metal Tiger. The balancing consideration of £112,500 is payable by Red Rock Resources and we would refer readers to their market announcement in this regard. At the close of business on 27 April 2016 the price of GRL shares was 1.65 pence and the market capitalisation of GRL was £1.027m. In the six months to 30 June 2015 GRL reported pre-tax losses of £813,206 and net assets of £730,423. Paul Johnson, Chief Executive Officer of Metal Tiger plc excluded himself from the decision to proceed with this acquisition being an existing holder of Goldstone Resources shares. Terry Grammer, Chairman of Metal Tiger commented "We are pleased to announce the strategic acquisition of shares in another UK listed operating resource company. Metal Tiger continues to build its investment in low valuation clean operating vehicles and anticipates further transactions of this nature will be undertaken in the near future.

Dropped on less than 5k worth of trades! MM are taking the p! Mind you why buy shares in a company with no debt,no need for placing,3.5m in the bank,income from one of cheapest producing goldmines in the world and news expected on several fronts on other assets. Certainly not one for the savvy pi it seems.

All I can see are disgruntled SH complaining of dilution through discounted placings and future warrants etc etc Yet here is a company with no debt! 3.5m in the bank! Income stream building fast from one of the lowest cost gold mines in the world! News moving forward/due on their other assets! And it stays overlooked?! Madness imho.

and newsflow just keeps getting better and better! PG 476p target may well become a reality! Zak mir has 225p in his sights. GL.

~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~ Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces positive pharmacokinetic data with its Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome. The pilot preclinical study confirmed the systemic release profile of Midatech's Q-Octreotide compared favourably with the reference Octreotide product and current market leader, Sandostatin® LAR Depot (Novartis). Commenting on the announcement, Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Q-Octreotide is one of the most advanced of our in-house cancer treatments. Whilst preparing the programme for clinical development, the existing use of Octreotide gives us confidence that this programme can be progressed quickly. We look forward to continuing to develop our internal pipeline of cancer therapies with Q-Octreotide near the front. Furthermore we are delighted now to be progressing with the investment in commercial scale up of production in our Bilbao facility in Spain, which will enable Q-Octreotide and other projects to be manufactured in-house, enabling us to capture more of the integrated value chain." MTD201, a sustained release version of Octreotide, is used to treat the incapacitating symptoms of metastatic carcinoid tumours, where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease, and to normalise the over-production of growth hormone in people suffering acromegaly who have had inadequate response to other therapies. Midatech plans on submitting its investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) and begin bio-equivalence studies in late 2016. Q-Octreotide is a wholly-owned asset of Midatech Pharma and will continue to be developed in-house. Subject to regulatory approval, Midatech expects to commercialize Q-Octreotide in the United States through its Midatech Pharma U.S. subsidiary.

Start and I do believe news is beginning to spread that income from Altintepe is going to transform the company! Presentation on 10th May could include some hard numbers and other news due on a number of fronts. GL

And about time too!!!!!

Reiterate buy with target 476!

Starting to build up! Could be last chance at these prices!

GRL on the rise again.Think news of some sort coming very soon! Remember we own 33.45% and recently lent them $100000 to continue! Something good coming our way!

Big deal lots of info but placing at 60p!

Don't forget 3.5m in the bank and no debt!

The pipeline keeps building and looking forward to sales updates on others soon! Midatech achieves positive dosing data for OpsiSporin Uveitis programme ~ Programme is delivering on track for an IND in H2 2017 ~ Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces positive data from its OpsiSporin (MTD202) programme, a sustained release treatment with Q-Cyclosporin for the treatment of non-infective uveitis. In a recent study to evaluate the efficacy of MTD202 in a preclinical model of Experimental Autoimmune Uveitis (EAU), a strong dose response profile was demonstrated at 15ug, 50ug and 150ug per eye. Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "This is a significant milestone in our own R&D pipeline and we are on track to advance this programme into the clinic. With the product attributes of being steroid and immunosuppressant sparing there is now full justification to progress the programme through to commercial development so we are now preparing for an IND in 2017. Currently, there is no approved intravitreal cyclosporine or other immunosuppressant treatment option available for patients. We see OpsiSporin as another important programme in our rapidly evolving pipeline." Uveitis is an inflammatory disorder affecting the iris, the ciliary body and the choroid layer of the eye, and can result in significant vision loss. Uveitis is estimated to be responsible for approximately 10%-20% of the blindness in the United States1. The uveitis market is growing rapidly and is today worth approximately $1.3 billion. The disorder is currently treated by eye drops, immuno-supressives or systemic drugs. MTD202 uses Midatech's microsphere technology for long-acting drug delivery. The drug is delivered intravitreal at 1000-fold lower doses than oral cyclosporine and a formal Investigational New Drug (IND2) enabling and toxicology program is now being finalised prior to an expected IND submission in the second half of 2017.

Strong finish today! PR will eventually get the message to sink in Along with the positive newsflow coming from the other assets Presentation on the 10th may have some better figures re the gold mine and I wouldn't be surprised to see further RNS' prior to this. GL

Good to see they are upping the PR. Market will have to take this seriously very soon. Mining Capital Conference Stratex International Plc, the AIM-quoted exploration and development company focused on gold and base metals in East Africa, West Africa and Turkey, where it holds a 45% interest in a producing gold mine, announces that it will be presenting at Proactive Investor's Mining Capital Conference on Tuesday 10th May 2016.